Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, saw its stock climb on the heels of this encouraging analyst action.

Mizuho raised its target price for Amylyx Pharmaceuticals from $16 to $18, signaling increased confidence in the company's future prospects. This upward revision likely contributed to the pre-market rally, as investors responded positively to the more optimistic valuation.

The increase in target price could reflect growing optimism about Amylyx's drug pipeline or recent developments in its research and development efforts. While specific reasons for the target price adjustment were not provided in the news, such changes often stem from improved outlooks on a company's financial performance, market position, or potential breakthroughs in drug development. Investors will be watching closely to see if this pre-market momentum carries into regular trading hours and whether Amylyx can sustain this upward trend.